

Postmenopausal Osteoporosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region, and Competition

<https://marketpublishers.com/r/P8304BFC8A40EN.html>

Date: February 2024

Pages: 182

Price: US\$ 4,900.00 (Single User License)

ID: P8304BFC8A40EN

Abstracts

Global Postmenopausal Osteoporosis Treatment Market was valued at USD 9.18 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.05% through 2029. The global postmenopausal osteoporosis treatment market refers to the pharmaceutical and therapeutic interventions aimed at managing and mitigating the effects of osteoporosis in women who have reached menopause. Osteoporosis is a common condition characterized by a decrease in bone density and an increased risk of fractures, particularly in postmenopausal women due to hormonal changes.

Key Market Drivers

Aging Population and Demographic Shifts

The global healthcare landscape is undergoing a transformative shift, driven by the aging population and significant demographic changes. Among the health challenges that arise with an aging society, postmenopausal osteoporosis stands out as a critical concern. As life expectancy continues to rise worldwide, an aging population becomes a

dominant demographic trend. With aging, the risk of developing postmenopausal osteoporosis increases due to hormonal changes and declining bone density. Osteoporosis, characterized by fragile and brittle bones, poses a significant threat to the health and well-being of the elderly, particularly postmenopausal women. This demographic shift has far-reaching implications, influencing healthcare priorities and driving demand for effective treatments. The aging population contributes to a surge in the prevalence of postmenopausal osteoporosis. As women live longer, a higher percentage enter the postmenopausal phase, amplifying the need for targeted osteoporosis treatments. The resulting increase in the patient pool directly correlates with a rising demand for pharmaceutical interventions and therapeutic solutions to manage bone health. The prominence of osteoporosis in an aging demographic has spurred heightened awareness among both healthcare providers and the general population. Recognizing the potential consequences of untreated osteoporosis, individuals are more likely to seek medical attention, leading to earlier diagnosis and intervention. This proactive approach drives the demand for postmenopausal osteoporosis treatments, creating opportunities for market growth. The healthcare expenditure associated with an aging population has a direct impact on the global postmenopausal osteoporosis treatment market. Governments and healthcare systems allocate resources to address the specific health needs of the elderly, including osteoporosis management. The integration of osteoporosis prevention and treatment into public health policies further bolsters the market by ensuring accessibility to quality care and treatments. The aging population presents an incentive for pharmaceutical companies, research institutions, and healthcare professionals to invest in research and innovation. The growing patient population drives the development of advanced treatment options, novel drug formulations, and therapeutic approaches tailored to postmenopausal osteoporosis. This commitment to innovation contributes to the expansion and diversification of the treatment market.

Rising Awareness and Diagnostic Advancements

In an era marked by evolving healthcare landscapes and innovative medical technologies, rising awareness and diagnostic advancements have emerged as powerful drivers of change. Nowhere is this impact more evident than in the field of postmenopausal osteoporosis treatment. As global awareness about the importance of bone health grows, coupled with cutting-edge diagnostic tools, the global postmenopausal osteoporosis treatment market is experiencing a transformative surge. Rising awareness initiatives, spearheaded by healthcare organizations, advocacy groups, and educational campaigns, have placed postmenopausal osteoporosis on the global health agenda. These efforts educate the public about the risks, symptoms, and

preventive measures associated with the condition. By informing individuals about the significance of bone health, people are empowered to take proactive steps to safeguard their well-being. As awareness increases, the demand for early diagnosis and treatment options naturally follows suit. Diagnostic advancements have revolutionized the way postmenopausal osteoporosis is detected and managed. Techniques like dual-energy X-ray absorptiometry (DXA) scans provide accurate measurements of bone mineral density and fracture risk, allowing healthcare professionals to identify the condition in its early stages. Early detection facilitates timely intervention, preventing the progression of bone loss and reducing the risk of debilitating fractures. These advancements emphasize the importance of regular check-ups and enable personalized treatment plans. With increased awareness comes greater recognition of the significance of bone health among healthcare providers. As a result, more postmenopausal women are screened for osteoporosis, expanding the potential patient pool. This expanded reach heightens the demand for effective treatments, prompting pharmaceutical companies to develop a diverse range of therapeutic interventions to cater to the needs of a broader demographic. The convergence of awareness and diagnostic advancements has paved the way for innovations in patient care delivery. Telemedicine and remote monitoring platforms allow healthcare providers to engage with patients beyond traditional clinical settings. Regular consultations, treatment adjustments, and follow-ups can now be conducted remotely, promoting patient compliance and reducing barriers to care. This revolution in healthcare access enhances patient engagement and promotes the adoption of osteoporosis treatments.

Innovative Pharmaceutical Interventions

In the realm of modern healthcare, innovative pharmaceutical interventions are wielding their transformative power, redefining the treatment landscape for a range of conditions. Among these, postmenopausal osteoporosis takes center stage as an area witnessing remarkable advancements. Innovative pharmaceutical interventions have ushered in a new era of diversified treatment options for postmenopausal osteoporosis. Beyond conventional therapies, cutting-edge drugs and treatments are being developed to target the root causes of bone loss. Selective estrogen receptor modulators (SERMs), bisphosphonates, calcitonin, and hormone replacement therapies are paving the way for personalized treatment plans that cater to the unique needs of each patient. Monoclonal antibodies (mAbs) and biologic agents represent a groundbreaking class of pharmaceutical interventions in postmenopausal osteoporosis treatment. Drugs like denosumab, a human monoclonal antibody, offer targeted mechanisms of action, inhibiting bone resorption and preserving bone mass. These innovative therapies demonstrate the potential to reduce fracture risk and improve overall bone health, thus

fueling market growth. An exciting development in the treatment landscape is the emergence of anabolic agents that stimulate bone formation. Teriparatide, a recombinant parathyroid hormone, is a notable example. By promoting bone growth and increasing bone mineral density, anabolic agents offer a promising avenue for patients with severe osteoporosis, contributing to the expansion of treatment options.

Key Market Challenges

Low Awareness and Underdiagnosis

One of the most significant challenges is the lack of awareness surrounding postmenopausal osteoporosis. Many individuals, including healthcare providers, underestimate the severity of the condition and its impact on bone health. This leads to underdiagnosis, delayed intervention, and missed opportunities for early treatment. Raising awareness through educational campaigns and improved medical training is essential to ensure timely diagnosis and treatment initiation.

Medication Adherence and Persistence

Ensuring consistent medication adherence and persistence is a persistent challenge in the treatment of postmenopausal osteoporosis. Some patients may find it difficult to adhere to complex dosing schedules or experience side effects that deter them from continuing their treatment. Healthcare providers must prioritize patient education, engage in open communication, and explore simplified dosing regimens to enhance medication adherence.

Side Effects and Safety Concerns

While pharmaceutical interventions play a crucial role in managing postmenopausal osteoporosis, certain treatments may be associated with side effects or safety concerns. Patients and healthcare providers often weigh the benefits against potential risks, impacting treatment decisions. The development of newer, safer treatment options and comprehensive patient counseling on potential side effects can help address this challenge.

Key Market Trends

Biologic and Monoclonal Antibody Therapies

Biologic and monoclonal antibody therapies are gaining prominence in the postmenopausal osteoporosis treatment market. Drugs like denosumab, a human monoclonal antibody, offer targeted mechanisms of action that inhibit bone resorption and foster bone health. These innovative therapies hold the promise of reducing fracture risk and improving overall bone density, marking a significant shift in treatment paradigms.

Anabolic Agents for Bone Formation

Anabolic agents, which stimulate bone formation, represent a notable trend in postmenopausal osteoporosis treatment. Drugs like teriparatide, a recombinant parathyroid hormone, enhance bone growth and increase bone mineral density. These agents are transforming the landscape by addressing the root causes of bone loss, offering patients a novel approach to managing osteoporosis.

Regenerative Therapies and Tissue Engineering

Regenerative therapies and tissue engineering are on the horizon of postmenopausal osteoporosis treatment. Stem cell treatments and other regenerative techniques hold the potential to repair damaged bones and restore bone health, presenting a futuristic avenue for therapeutic interventions. While still in the experimental stages, these treatments are generating excitement and opening new avenues for research.

Segmental Insights

Drug Type Insights

In 2023, the global postmenopausal osteoporosis treatment market was dominated by the bisphosphonates segment. Bisphosphonates predominate on the market as the first line of treatment for osteoporosis. Additionally, drugs containing bisphosphonates lessen bone loss by lowering osteoclast activity and improving bone form and density. The market's fastest-growing sub-segment is hormone replacement therapy. There is a growing market need for therapeutic areas that are safe & effective in comparison to others while providing minimum hazards due to the increased acceptance of hormone replacement treatment products and an increase in the prevalence of growth hormone insufficiency in major countries. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2024 to 2029.

Distribution Channel Insights

In 2023, the global postmenopausal osteoporosis treatment market was dominated by retail pharmacies. In 2023, the retail pharmacy distribution channel segment held the majority of the market. This was due to a number of variables, including the patient's high compatibility with retail pharmacies as a result of the prolonged course of therapy, increasing cooperation with orthopaedic centres that help manage osteoporosis, and others.

Regional Insights

The North America region has established itself as the leader in the global postmenopausal osteoporosis treatment market. In 2023, North America held the highest share of the global market for postmenopausal osteoporosis treatment. Due to factors like a strong industry presence, well-developed healthcare infrastructure, high rates of accurate diagnosis and effective treatment, higher patient compliance, and a sizable patient population, North America accounted for the largest share of global revenue in 2023. According to the Centres for Disease Control & Prevention (CDC), 18.8% of women who were 50 years of age or older had osteoporosis in 2021. The prevalence is expected to increase even more as a result of sedentary lifestyles or bad eating and drinking practices.

Key Market Players

Teva Pharmaceutical Industries Ltd

Pfizer Inc

Merck & Co

Novartis Pharma AG

Eli Lilly and Co Ltd

AbbVie Inc

Hoffmann-La Roche Ltd

Cipla Ltd

Amgen Inc

Report Scope:

In this report, the Global Postmenopausal Osteoporosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Postmenopausal Osteoporosis Treatment Market, By Drug Type:

Bisphosphonates

Vitamin D3

Estrogen Agonist/Antagonist

Hormone Replacement Therapy

Parathyroid Hormone Therapy

Others

Postmenopausal Osteoporosis Treatment Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Others

Postmenopausal Osteoporosis Treatment Market, By Region:

North America

United States

Canada

Mexico

Europe

France

Germany

United Kingdom

Italy

Spain

Asia-Pacific

China

India

South Korea

Japan

Australia

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Postmenopausal Osteoporosis Treatment Market.

Available Customizations:

Global Postmenopausal Osteoporosis Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others)
 - 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
 - 5.2.3. By Region

- 5.2.4. By Company (2023)
- 5.3. Market Map

6. NORTH AMERICA POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others)
 - 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
 - 6.2.3. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Postmenopausal Osteoporosis Treatment Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Drug Type
 - 6.3.1.2.2. By Distribution Channel
 - 6.3.2. Canada Postmenopausal Osteoporosis Treatment Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Drug Type
 - 6.3.2.2.2. By Distribution Channel
 - 6.3.3. Mexico Postmenopausal Osteoporosis Treatment Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Drug Type
 - 6.3.3.2.2. By Distribution Channel

7. EUROPE POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast

7.2.1. By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others)

7.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1. France Postmenopausal Osteoporosis Treatment Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Drug Type

7.3.1.2.2. By Distribution Channel

7.3.2. Germany Postmenopausal Osteoporosis Treatment Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Drug Type

7.3.2.2.2. By Distribution Channel

7.3.3. United Kingdom Postmenopausal Osteoporosis Treatment Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Drug Type

7.3.3.2.2. By Distribution Channel

7.3.4. Italy Postmenopausal Osteoporosis Treatment Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Drug Type

7.3.4.2.2. By Distribution Channel

7.3.5. Spain Postmenopausal Osteoporosis Treatment Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Drug Type

7.3.5.2.2. By Distribution Channel

8. ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others)

8.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

8.2.3. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Postmenopausal Osteoporosis Treatment Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Type

8.3.1.2.2. By Distribution Channel

8.3.2. India Postmenopausal Osteoporosis Treatment Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Type

8.3.2.2.2. By Distribution Channel

8.3.3. South Korea Postmenopausal Osteoporosis Treatment Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Type

8.3.3.2.2. By Distribution Channel

8.3.4. Japan Postmenopausal Osteoporosis Treatment Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Drug Type

8.3.4.2.2. By Distribution Channel

8.3.5. Australia Postmenopausal Osteoporosis Treatment Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Drug Type

8.3.5.2.2. By Distribution Channel

9. SOUTH AMERICA POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others)

9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

9.2.3. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Postmenopausal Osteoporosis Treatment Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Drug Type

9.3.1.2.2. By Distribution Channel

9.3.2. Argentina Postmenopausal Osteoporosis Treatment Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Drug Type

9.3.2.2.2. By Distribution Channel

9.3.3. Colombia Postmenopausal Osteoporosis Treatment Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Drug Type

9.3.3.2.2. By Distribution Channel

10. MIDDLE EAST AND AFRICA POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others)

10.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

- 10.2.3. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Postmenopausal Osteoporosis Treatment Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Drug Type
 - 10.3.1.2.2. By Distribution Channel
 - 10.3.2. Saudi Arabia Postmenopausal Osteoporosis Treatment Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Drug Type
 - 10.3.2.2.2. By Distribution Channel
 - 10.3.3. UAE Postmenopausal Osteoporosis Treatment Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Drug Type
 - 10.3.3.2.2. By Distribution Channel
 - 10.3.4. Kuwait Postmenopausal Osteoporosis Treatment Market Outlook
 - 10.3.4.1. Market Size & Forecast
 - 10.3.4.1.1. By Value
 - 10.3.4.2. Market Share & Forecast
 - 10.3.4.2.1. By Drug Type
 - 10.3.4.2.2. By Distribution Channel

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. POLICY & REGULATORY LANDSCAPE

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product

15. COMPETITIVE LANDSCAPE

- 15.1. Teva Pharmaceutical Industries Ltd
 - 15.1.1. Business Overview
 - 15.1.2. Company Snapshot
 - 15.1.3. Products & Services
 - 15.1.4. Financials (As Reported)
 - 15.1.5. Recent Developments
 - 15.1.6. Key Personnel Details
 - 15.1.7. SWOT Analysis
- 15.2. Pfizer Inc
- 15.3. Merck & Co
- 15.4. Novartis Pharma AG
- 15.5. Eli Lilly and Co Ltd
- 15.6. AbbVie Inc
- 15.7. Hoffmann-La Roche Ltd
- 15.8. Cipla Ltd
- 15.9. Amgen Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Postmenopausal Osteoporosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist/Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region, and Competition

Product link: <https://marketpublishers.com/r/P8304BFC8A40EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8304BFC8A40EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970